Astellas Sees Path Forward for Gene Therapy Despite Four Patient Deaths

Despite four pediatric patient deaths and an ongoing clinical hold by the FDA, new trial data released Wednesday by Astellas suggests its gene replacement therapy AT132 for X-linked myotubular myopathy is still viable as a potential treatment option.